Intranasal delivery of beta2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor

Abstract

A method of improving cognition in a patient with Down syndrome, which entails intranasally administering one or more β2-ADR agonists or pharmaceutically-acceptable salts of either or both to the patient in an amount and with a frequency effective to improve cognition of the patient as measured contextual learning tests.

1 .- 12 . (canceled) 
     
     
         13 . A method of improving cognitive function in a subject having Alzheimer's disease, said method comprises a step of intranasally administering of one or more β2-adrenergic (β2-ADR) agonist or a pharmaceutically acceptable salt thereof to said subject in an amount and with a frequency of administration effective to improve the cognitive function of said subject. 
     
     
         14 .- 15 . (canceled) 
     
     
         16 . The method of  claim 13 , wherein said β2-ADR agonist is a short acting β2-ADR agonist. 
     
     
         17 . The method of  claim 13 , wherein said β2-ADR agonist is a long acting β2-ADR agonist. 
     
     
         18 . The method of  claim 13 , wherein said β2-ADR agonist is an ultra long acting β2-ADR agonist. 
     
     
         19 . The method of  claim 13 , wherein said β2-ADR agonist is selected from the group consisting of salbutamol, levosalbutamol, terbuline, pirbuterol, procaterol, metaproterenol, bitolterol mesylate, oritodrine, isoprenaline, salmefamol, fenoterol, terbutaline, albuterol, isoetharine, salmeterol, bambuterol, formoterol, clenbuterol and indacaterol. 
     
     
         20 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered without any co-administration of one or more β2-ADR antagonist. 
     
     
         21 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered without any prior administration of one or more β2-ADR antagonist. 
     
     
         22 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered without any prior or co-administration of one or more β2-ADR antagonist. 
     
     
         23 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered at 2 to 100 mg per administration. 
     
     
         24 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered at 5 to 30 mg per administration. 
     
     
         25 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered once weekly. 
     
     
         26 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered twice weekly. 
     
     
         27 . The method of  claim 13 , wherein said one or more β2-ADR agonist are administered once per month. 
     
     
         28 . The method of  claim 13 , wherein said one or more β2-ADR agonist is intranasally administered in a 0.9% by weight sterile aqueous saline solution. 
     
     
         29 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered in an aqueous sterile saline or dextrose saline solution suitable for intranasal administration, and wherein the concentration of one or more β2-ADR agonist in the aqueous based solvent is about 2 μg/l to about 20 μg/l. 
     
     
         30 . The method of  claim 13 , wherein said one or more β2-ADR agonist is intranasally administered in an aqueous sterile saline or dextrose saline solution, and wherein the concentration of one or more β2-ADR agonist in the aqueous based solvent is about 5 μg/l to about 15 μg/l. 
     
     
         31 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered at 0.05 to 10.05 mg/kg of body weight. 
     
     
         32 . The method of  claim 13 , wherein said one or more β2-ADR agonist is administered at 0.05 to 3.0 mg/kg of body weight.